List view / Grid view

Catalent

 

21st Anniversary Supplement

21 December 2017 | By

European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.

Continuous manufacturing: regulatory and quality assurance challenges

22 August 2017 | By , ,

During 2002, the United States Food and Drug Administration (FDA) requested rationalisation and modernisation of the manufacturing base for pharmaceutical production. This was in the hope that modernising the supply chain would enhance the robustness of manufacturing processes, thereby reducing product failures and, importantly, significantly enhancing product quality.1 The FDA’s…

Antibody Drug Conjugates (ADC)

19 February 2014 | By Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent

Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: "Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?"

Catalent presents at AAPS 2013

22 November 2013 | By Freddy White, European Pharmaceutical Review

Dr David Igo, Director of Product Development and Manufacturing at Catalent, presents their new FormProRx™ Web Tool to Freddy White at AAPS 2013.

Industry Expert Panel

21 February 2013 | By

Welcome to European Pharmaceutical Review’s Industry Expert Panel. We have assembled a panel of authoritative voices from the pharmaceutical industry to speak on a wide range of issues that affect this industry, sharing their expertise and insight with our readers.